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Introduction
Increasing pressure on the pharmaceutical
industry
Global competitiveness is becoming increa-
singly important for the pharmaceutical indus-
try. Companies are exploring options to enhan-
ce the efficiency of the resources they are using
at all stages of the whole value chain from disco-
very research to production and logistics as well
as sales and marketing. Especially innovation is
recognised as the cornerstone for competitive
advantage and is fostered by strong investments
in R&D (Achilladelis et al., 2001). Rising costs of
pharmaceutical R&D coupled with increasing
pressure of stakeholders demanding steady
growth lead to increasing pressure on the out-
put of the innovation pipeline. 
But drug development and commercialisati-
on is an expensive, lengthy and risky process. Stu-
dies published in 2003 report an average pre-tax
cost of approximately US$800 million to bring a
new drug to the market (DiMasi, 2002; DiMasi et
al., 2003). It is estimated that by the time a medi-
cinal product is placed on the market, an avera-
ge of 12-13 years will have elapsed since the syn-
thesis of the new active substance. Thereby, on
average, out of every 10,000 sub-stances synthe-
sised in laboratories, only one or two will success-
fully pass all the stages to become marketable
medicines (EFPIA, 2008). 
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of R&D has created new needs for specialised
technologies with the potential to reduce lead
times and streamline the drug discovery and deve-
lopment process. Cockburn, Henderson and Stern
(Cockburn et al., 2000) have shown that drug dis-
covery productivity is dependent on the internal
organisation of R&D. For these reasons, pharma-
ceutical companies have been forced to reassess
their mode of R&D operation including outsour-
cing activities (Quinn, 1999; Quinn, 2000). 
Outsourcing, traditionally thought of as a short-
term strategy for demand realisation, could be
considered to lever the core competencies to
increase performance in pharmaceutical R&D.
There are good arguments to stress the comple-
mentarity between in-house R&D and external
know-how (Arora et al., 1990; Arora et al., 1994;
Cassiman et al., 2002; Cockburn et al., 1998). For
example, Arora and Gambardella examined the
complementarity among sourcing strategies of
large companies in the biotechnology industry.
The access to external know-how may leverage
the productivity of internal R&D activities if the
organisation exhibits a willingness to absorb
external ideas (Veugelers, 1997; Veuglers et al.,
1999). An important task in innovation manage-
ment, therefore, is to integrate internal and exter-
nal knowledge within the innovation process, in
order to benefit from positive effects each activi-
ty has on the other. 
But outsourcing R&D also bears potential risks
due to project complexity und loss of flexibility.
Studies to clarify the comparative effect of out-
sourcing in relation to internal improvements
within manufacturing processes showed that
internal enhancement of manufacturing capa-
bility made it much easier to predict improve-
ments in operating performance than outsour-
cing (Dabhilkar et al., 2008). Generally, outsour-
cing leads to negative effects when used only as
a cost reducing strategy to improve short-term
performance. The consequence may be the loss
of internal know-how and expertise as well as
higher total costs in the long-term. There are
numerous examples where insourcing preven-
ted the negative effects caused by bad outsour-
cing decisions (The Economist, 1996). 
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Research question and methodology
This paper discusses how the challenges facing
the pharmaceutical industry are shaping “make-
or-buy” strategies within pharmaceutical R&D.
Pharmaceutical industry includes also the bio-
technology industry which is strongly linked to
the pharmaceutical industry. The discussion of
outsourcing will use the example of chemical
synthesis offered by specialised service providers
within the drug discovery and development pro-
cess. This example is chosen as it covers an impor-
tant part of the drug discovery and development
process and represents the outsourcing menta-
lity in pharmaceutical very well.
The empirical data have been collected through
desk research and interviews with managers and
experts of 19 different pharmaceutical compa-
nies and 12 pharmaceutical service providers in
different rounds between 2002 and 2005 (Figu-
re 1). An interview guideline with a reference set
of questions was developed to secure the compa-
rability of the answers and to leave enough room
for spontaneous answers, which gave a semi-
structured nature to the interviews. Each inter-
viewee was interviewed in sessions of approxi-
mately 60 minutes, whereby most of the inter-
views were conducted face-to-face and only a few
by telephone. 
Additionally, in early 2008, the outsourcing
behaviour in the field of chemical synthesis of
the interviewed companies and 61 additional
pharmaceutical and biotechnology companies
was analysed through desk research using diffe-
rent public sources (e.g. business databases) and
company disclosures (e.g. websites and press
releases). Additional telephone calls with per-
sons responsible for chemical synthesis clarified
open questions, which could not be answered
using other sources.
Results of analysis and interviews
Outsourcing behaviour of pharmaceutical
companies
Outsourcing activities are well established
along the whole pharmaceutical R&D and pro-
duction value chain from discovery research to
packaging and logistics (Figure 2). Most of the
outsourced services are used in one or more pro-
cess steps of the value chain. The analysis and
interviews showed that the differentiation bet-
ween traditional and emerging pharmaceutical
companies is of importance. Traditional pharma-
ceutical companies, which could be large (“big
pharma”) or mid-sized companies, normally cover
the whole or most of the pharmaceutical value
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Figure 2 Outsourcing activities along the pharmaceutical R&D and production value chain
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chain from drug discovery/development up to
production and marketing/sales. A widely used
term for this kind of company is “Fully Integra-
ted Pharmaceutical Company” (FIPCO). In con-
trast, emerging pharmaceutical companies are
focused on selected stages of the pharmaceuti-
cal value chain (Van Arnum, 2008). Most of the
biotechnology start-up companies or other tech-
nology driven companies with their roots in R&D
are part of this group. 
Most traditional pharmaceutical companies
have their own in-house capacities and the open-
ness for outsourcing is significantly lower com-
pared to emerging companies (Figure 3). They are
less interested in buying services due to suffi-
cient in-house capacities. Also cost reduction
(reducing fixed costs or reducing people on the
payroll) is not so important for outsourcing of
services than always thought. These companies
have a high interest in additional, external know-
how which is not available in-house or too expen-
sive, if it was to be built up internally. Expanding
in-house capabilities by external expertise is seen
as the most important advantage of using exter-
nal services. Discovery research and clinical tri-
als are good examples and show the highest out-
sourcing degree. Within these areas the major
requirements in cooperating with services pro-
viders are: 
Leading edge equipment and know-how of
the provider while adhering to the highest
possible technical standards.
Clear competence profile of the chemical pro-
vider focused on specific segments while be-
ing unique and innovative.
International presence and availability of
experts to support the customer worldwide.
Highly standardised co-operation model cover-
ed by general agreements with precise defi-
nition of the ownership of intellectual proper-
ty.
Compared to traditional companies, the out-
sourcing level of emerging pharmaceutical com-
panies is generally rather high and in some cate-
gories 100% due to low or missing internal resour-
ces. These companies see outsourcing as an effecti-
© 2010 Institute of Business Administration
Gunter Festel, Alexander Schicker and Roman Boutellier 
Journal of Business Chemistry 2010, 7 (2)
Figure 3 Percentage of companies using outsourcing differentiated between traditional and emerging pharmaceutical
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ve method to capture capacity and expertise wit-
hout investing much money in in-house resour-
ces. In particular, many start-ups lack experience
and expertise around drug development, which
consequently forces them to relay on external
service providers. In doing this, they have the fol-
lowing requirements.
Lean and flexible development capacities on
the side of the providers, easily adaptable to
smaller demands.
Full service range and know-how around che-
mical synthesis with capabilities for the sup-
port of project management.
Transparent and flexible cost structures, simi-
lar or equivalent to own in-house structures
to avoid additional administrative resource
burdens.
Cooperation models for outsourced services
In the areas of pharmaceutical R&D and pro-
duction, four different co-operation models bet-
ween pharmaceutical companies as customer
and service providers as vendors have been estab-
lished, depending on goal congruence and mea-
surability of results. There is a simple correlati-
on: the higher the goal congruence, the more trust
between the two partners, and the higher the
measurability of results, the closer the relations-
hip comes to a traditional customer-supplier rela-
tionship (Figure 4).
Project selection: Selection of service provi-
ders on a project-by-project basis from a core
list of preselected service providers. The ser-
vice providers are engaged according to the
fit of their core competence to the specific pro-
ject requirements (e.g. the choice of the best-
fitting clinical research organisation for the
management of clinical trials in a special the-
rapeutic area and/or a special phase of the
drug development process).
Price competition: Long list of service provi-
ders systematically put into competition in
order to secure lowest purchasing prices. This
model is less strategically oriented, but rather
serves to achieve the demand for the most
cost-efficient fulfilment (e.g. purchase of stan-
dardised analytical services for routine ana-
lytical tasks within drug development or qua-
lity management). It can be applied success-
fully only if the outcome can be measured
easily.
Strategic partnership: Strategic links with a
handful of preferred service providers who
are given preferential “right of first refusal”.
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Figure 4 Different types of cooperation models for outsourced services
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A framework contract covers all the relevant
services (e.g. contracts with full-service drug
discovery service providers like Albany Mo-
lecular Research). 
Joint venture: If the results depend on both
parties, but contribution cannot be easily attrib-
uted, a 50-50 joint venture is a good choice.
This approach has not been observed between
a pharmaceutical and a service provider. It is
a well-known approach in other industries,
e.g. in fuel cells, or high-tech in general. 
The pharmaceutical industry invests high
management capacity in choosing appropriate
service providers and to commit them to the com-
pany to achieve goal congruence. Stringent inspec-
tion of the supplier's facility, quality, best practi-
ces, trained staff and certified processes is cruci-
al in the selection process (Findlay, 2007). Assess-
ment of the service provider's financial stability
is imperative during the selection process. As
these suppliers work with various projects from
pharmaceutical companies, it becomes crucial to
ensure there is no backlog of projects due to finan-
cial constraints. 
Analysing the relevance of the cooperation
models for the different outsourcing areas shows
that the most often used cooperation model is
“project selection” (Figure 5). The “strategic part-
nership” model is used mainly in the areas of dis-
covery research and chemical synthesis. ”Price
competition” is mainly used for services in the
area of pharmacology & toxicology, analytics,
regulatory support and logistics, fields where the
deliverables are easy to control. The “Joint ven-
ture” model between pharmaceutical companies
and service providers is more of theoretical nature,
as it not often found in practice. But there are
some joint ventures between service providers,
especially to cover emerging markets. A good
example is the formation of the joint venture Evo-
tec-RSIL in India between Research Support Inter-
national (RSIL) and Evotec to design, synthesise
and manage compound libraries as a service. The
joint venture combines Evotec's expertise in libra-
ry design, synthesis, analysis, purification and
project management with RSIL's synthesis exper-
tise coupled with a low cost structure in India. 
Chemical synthesis services as example for
strategic partnerships
The “strategic partnership” model is analysed
more in detail as it is perceived that this model
has the potential to improve the performance of
pharmaceutical R&D significantly. For a better
Journal of Business Chemistry 2010, 7 (2)© 2010 Institute of Business Administration






	





&
#
)
%+ 
%&

%
 

!

  &
+"
'
&&
 

%!

# #
+
 
 '#
* 
# #
+
 
 
"
  
'%
 &  
"
 +
'
& 

(
 '
#%+
 &(
$$
#%'
 
%
#
&
& 
)
 #
$!
"
' 
#
%!
( 
'#
" 
)
 #
$!
"
' 
%
(
 &(
&
'"

 $%
#
(
'#
" 
#
&

 #
%!
 $%
#
(
'#
" 



"
 
#
&
'
& 
'%' $%'"%&$ %#' & '#" % #!$''#"
Figure 5 Relevance of the co-operation models for the different outsourcing areas
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understanding of the “strategic partnership”
model, the field of chemical synthesis should
serve as an example. 
Traditional outsourcing concepts within che-
mical synthesis are focused on single product or
service. Only the product (e.g. lead compound or
class) is sold exclusively or semi-exclusively to
the customer with the provider remaining the
owner of the synthesis know-how and process
design. Contracts have been rather complex in
the past due to opposing views on intellectual
property and rigid customer provider relations.
Therefore, both partners are forced to think and
act much more result-oriented than react within
existing organisational boundaries. Service offe-
rings in outsourcing need to be adapted, while
interfaces between customer and service provi-
der, reduced and redefined. A solution is “body
leasing”: integrating external experts into inter-
nal R&D teams to support R&D projects more fle-
xibly and more timely within pharmaceutical
companies. Many “strategic partnership” models
are based on service providers hiring out their
employees with specialised skills and leaving
intellectual property rights in the ownership of
their pharmaceutical customers (Figure 6). 
This represents a switch from isolated service
offerings to an integrated platform of support
within the customer’s processes and structures.
This means that pharmaceutical companies hire
in experts for a defined period and integrate them
into their in-house R&D structure. Hired experts
use either their own in-house infrastructure or
facilities inside the customer’s organisation. A
project management team for which the custo-
mer is responsible guarantees success of the deve-
lopment project as well as the intensive know-
how and expertise transfer. A highly standardi-
sed project management is important to ensure
success. This addresses pharmaceutical industry
concerns of minimising third party activities for
critical path activities through highly standardi-
sed processes. 
Experiences and learning effects 
Cost, time and innovation are the levers to
improve R&D performance and R&D outsourcing
could give the mentioned levers a positive impact.
The positive effects of outsourcing are enhanced
if the supplier is used to supplement existing core
competencies (i.e. to free resources in order to
invest in higher internal capability). Besides limi-
ting fixed costs, service providers can often pro-
vide the expertise and know-how in a more fle-
xible and cost-effective way than internal resour-
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Figure 6 “Strategic partnership” model as outsourcing concept
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ces. Furthermore, the complementarity between
in-house R&D and external know-how creates
additional benefits regarding the quality of
research and services. Therefore, the right stra-
tegic partner could not only offer cost advantages,
but also quality improvement and innovation,
and the “strategic partnership” model guaran-
tees a high internal competence level in the long-
term.
But nevertheless, some aspects like perceived
(or real) difficulties to transfer know-how and
issues with intellectual property situation are
seen as major obstacles for outsourcing. Service
providers should react to the concerns of phar-
maceutical customers with a best practice ap-
proach which includes the following aspects. 
Complexity and efficiency: definition of highly
standardised and transparent processes and
contracts.
Co-operation and communication: project
management in close vicinity to the pharma-
ceutical company and not only offshore lab
resources (e.g. in China or India).
Costs and invoicing: establishing full cost trans-
parency and easy invoicing process.
Flexibility and quality: high flexibility regar-
ding project execution with stringent quali-
ty control.
Exclusivity and secrecy: clear and transparent
rules regarding the engagement in projects of
direct competitors.
Intellectual property: cooperation agreement
leaving all critical IP at the pharmaceutical
company.
If these aspects are handled properly, the pro-
fessional market for highly specialised services
and the flexible structures within the services
networks make pharmaceutical research more
efficient. In the future, highly specialised research
service providers will play a more important role
and integrative part of the processes in the phar-
ma industry. The result is that there has been an
increase in drugs introduced to the market over
the past years, after the number reached a low
point shortly after the turn of the millenium.
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